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Triple-negative breast cancer (TNBC) is the most aggressive subtype of
breast cancer with poor prognosis and high rates of relapse. The lack of
actionable targets for TNBC has contributed to the high mortality rates of
this disease, and new candidate molecules for potential manipulation are
urgently required. Here, we show that macrophage-stimulating protein
(MSP) and its tyrosine kinase receptor, Recepteur d’origine nantais
(RON), are potent drivers of cancer cell growth and tumor progression in
a mouse model of TNBC driven by the loss of Trp53 and Brca1. After
comparison of two genetically engineered mouse models of TNBC, we
found that mammary tumors from K14-Cre;Brca1F/F;Trp53F/F (KB1P)
mice exhibit high endogenous levels of MSP and RON expression. We
show that MSP stimulates serine/threonine kinase 1 and extracellular regu-
lated MAPK activation as well as cancer cell growth in cell lines derived
from the two mouse models, while genetic and pharmacological inhibition
of RON prevents these effects. Similarly, KB1P tumor progression in mice
was robustly attenuated by treatment with a RON inhibitor with accompa-
nied reduction in the proliferation marker, Ki-67. Analysis of human gene
expression data confirmed that the genes encoding MSP and RON are
robustly expressed in human TNBC as well as other subsets of breast can-
cer. Our findings uncover a mouse model where MSP expression and RON
expression are naturally increased, and they provide evidence that this
receptor and its ligand are viable candidate molecules for targeted treat-
ment of breast cancer.
1. Introduction
Triple-negative breast cancer (TNBC) represents a sub-
group of about 15–20% of breast tumors that lacks
expression of three main biomarkers: estrogen receptor
(ER), progesterone receptor, and epidermal growth
factor receptor 2 (HER2) amplification (Bianchini
et al., 2016). When compared to other breast cancer
subgroups, patients with TNBC generally have an
unfavorable prognosis due to the aggressive nature of
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this disease and higher risk of local and distant recur-
rence (Malorni et al., 2012). At the molecular level,
TNBC is highly heterogeneous, but unlike ER-positive
and HER2-amplified breast cancers, the discovery of
uniform actionable molecular targets has eluded
researchers (Bianchini et al., 2016). Thus, the absence
of approved targeted therapies for TNBC leaves
chemotherapy as the only therapeutic option.
Recepteur d’origine nantais (RON) is a receptor tyr-
osine kinase encoded by the MST1R gene that shares
high homology with the cMET oncogene (Yao et al.,
2013). RON is translated as a single-chain cytoplasmic
proprotein. It is further processed by proteolytic
enzymes into a mature form, consisting of two parts,
an alpha-chain and a beta-chain, held together by a
disulfide bridge. The mature RON protein is displayed
as a transmembrane protein at the cell surface. Addi-
tionally, several isoforms of the RON protein have
been reported that stem from two distinct promoters
upstream or within the MST1R gene—these two start
sites are conserved between human and mouse as well
(Yao et al., 2013). These isoforms can be constitutively
active, oncogenic, or biologically inactive (Yao et al.,
2013). RON isoforms are expressed in normal mam-
mary gland tissue, but can be overexpressed and phos-
phorylated in primary breast tumors (Maggiora et al.,
1998). RON has only one known ligand called macro-
phage-stimulating protein (MSP). MSP is encoded by
the Mst1 gene, and it is structurally similar to the
cMET ligand, hepatocyte growth factor. The short
form of the RON receptor lacks the extracellular
amino acids required for MSP binding, and this short
form is constitutively active in some human cancer cell
lines (Bardella et al., 2004). MSP and RON (over)-ex-
pression in breast cancer specimens correlates with
poor prognosis and distant recurrence (Lee et al.,
2005; Welm et al., 2007), suggesting that the MSP–
RON axis contributes to disease progression. Indeed,
experimental models, in which MSP or RON is over-
expressed or the RON receptor is inhibited or geneti-
cally deleted, show that the MSP–RON axis drives
mammary tumor progression and metastasis (Andrade
et al., 2017; Benight et al., 2015; Cunha et al., 2014;
Ekiz et al., 2018; Eyob et al., 2013; Faham et al.,
2018; Liu et al., 2011; Welm et al., 2007; Zinser et al.,
2006).
Here, we provide the first evidence of the impor-
tance of the MSP–RON axis in a clinically relevant,
autochthonous mouse models of TNBC. We used
K14-Cre;Trp53F/F (KP) and K14-Cre;Brca1F/F;Trp53F/
F (KB1P) mice which normally develop single tumors
in one mammary gland that histologically and tran-
scriptionally resemble invasive ductal carcinoma in
humans (Liu et al., 2007). When compared with
tumors from the KP model, tumors from the KB1P
model exhibit a high degree of genomic instability with
many chromosomal gains and losses, due to the loss of
Brca1. KB1P and KP mice exhibit an ~ 200-day differ-
ence in tumor-free survival and overall survival, with
KB1P mice succumbing earlier to tumor development
(Liu et al., 2007). In this study, we show that MSP
and RON are upregulated in mammary tumors from
KB1P mice when compared with tumors from KP
mice or normal mammary glands (MG). Novel cell
lines generated from KP and KB1P tumors display
increased serine/threonine kinase 1 (AKT) and extra-
cellular regulated MAPK (ERK1/2) activation in
response to MSP-mediated RON signaling. Moreover,
MSP stimulates proliferation of KP and KB1P cells
whereas inhibition of RON signaling decreases cell
growth in vitro and tumor growth in vivo. These data
support the notion that the RON receptor is an
actionable target in TNBC and provide a new plat-
form to study MSP–RON biology in a physiologically
relevant model.
2. Materials and methods
2.1. Animal models and cell lines
The generation and characterization of KP and KB1P
mice, which are maintained on the FVB/n background,
is described here (Liu et al., 2007). Single cell suspen-
sions from end-stage (15 mm) mammary tumors were
plated and propagated in hypoxic incubators for
4 weeks to generate cell lines. Individual cell lines (3
KP and 4 KB1P) were derived from independent
donor tumors that arose in different mice. These cells
were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS, 100 UmL1 penicillin/
streptomycin, and 2 mM glutamine. Before recombi-
nant MSP treatment (100 ngmL1; R&D Systems
#6244-MS-025, Abingdon, UK), cells were serum
starved in 0.2% FSC overnight. The RON inhibitor
BMS-777607 (ChemieTek #CT-BMS777, Indianapolis,
IN, USA) was added to cells at 1 lM for 1 h before
MSP treatment where indicated.
The orthotopic transplantation of tumor fragments
is described here (Doornebal et al., 2013). Briefly,
KB1P tumor fragments from one donor tumor were
implanted into the fourth mammary fat pad of 24- 10-
12-week-old female recipient FVB/n mice (Charles
River, Harlow, UK). When tumors reached
3 9 3 mm, mice were randomized into control or
experimental groups. Mice were given a daily oral
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gavage of BMS-777607 (50 mgkg1 dissolved in
DMSO and diluted in 70% poly(ethylene glycol)-300)
or vehicle control (11% DMSO diluted in 70% poly
(ethylene glycol)-300) for 10 days, and then monitored
until tumors reached 15 mm. A separate group of mice
were treated for 7 days, after which the experiment
was ended.
Mouse experiments were performed in accordance
with UK Home Office license numbers 70/8645 (Karen
Blyth), carried out inline with the Animals (Scientific
Procedures) Act 1986 and the EU Directive 2010, and
sanctioned by local Ethical Review Process (University
of Glasgow). Mice were housed on a 12/12-h light/
dark cycle and fed and watered ad libitum.
2.2. RNA sequencing analysis
Total tumor gene expression data from KP and KB1P
mice were kindly provided by Lewis Cantley (NCBI
BioProject #PRJNA398328). RNA isolation, DNA
library preparation, sequencing information, and gen-
eration of fragments per kilobase of transcript per mil-
lion mapped reads (FPKM) values for these data are
described here (Liu et al., 2018). To visualize the gene
expression, FPKM values were log transformed in R
version 3.5.0 (RStudio, Boston, MA, USA) and box-
plots generated with the ggplot2 package. Differences
between expression distributions were tested with the
Wilcoxon rank-sum test.
2.3. Quantitative real-time PCR
RNA was isolated from frozen KP and KB1P mam-
mary tumors or cell lines using Qiagen’s RNeasy kit
(Manchester, UK) and on-column DNA digestion.
RNA concentration and purity (cutoff = 1.8 260/280
ratio) was determined using a Thermo Scientific Nano-
Drop spectrophotometer with NanoDrop 2000 soft-
ware. cDNA was prepared from 1 lg RNA using a
Quantitect Reverse Transcription Kit (Qiagen) and
diluted 1 : 20 in DEPC-treated water. For quantitative
real-time PCR, 12.5 ng aliquots of cDNA were ampli-
fied in triplicate on an ABI 7500 real-time PCR
machine using SyGreen Blue Mix Lo-ROX PCR mas-
ter mix (PCR Biosystems, London, UK) and primers
for all isoforms of Mst1r (Mm_Mst1r_1-SG; Quanti-
tect) and Mst1 (Forward—CTCACCACTGAAT-
GACTTCCAG; Reverse—AAGGCCCGACAGTCCAG
AA) at 2.5 lM with endogenous controls Hprt
(Mm_Hprt_1_SG; Quantitect) and b-actin
(Mm_Actn_1_SG; Quantitect). Relative expression was
calculated by the DCt method after averaging endoge-
nous controls. Data are displayed as 1/DCt.
2.4. Western blotting
Protein was extracted from KP and KB1P mammary
tumors or cell lines using RIPA buffer (50 mM Tris/
HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% DOC,
0.1% SDS, 2 mM EDTA) complemented with 19 pro-
tease/phosphatase inhibitor cocktail (HALT 1009;
Thermo Fisher Scientific, Waltham, MA, USA). Mam-
mary tumor tissue was physically disrupted in the
same mix with Precellys Hard Tissue beads (VWR)
using a rotor-stator homogenizer until uniformly
homogenous. Lysates were clarified by centrifugation,
and protein levels were quantified using a BCA protein
assay kit (Thermo Fisher Scientific). Protein samples
(50 lg) were resolved on two 4–12% NuPage poly-
acrylamide gels (Invitrogen) and transferred onto
enhanced chemiluminescence nitrocellulose membranes
using an iBlot2 Transblot Turbo Transfer System
(Invitrogen, Waltham, MA, USA) for experimental
tests and sample integrity controls. Primary antibodies
were incubated overnight at 4 °C on blocked mem-
branes: anti-RON (500 ngmL1; Thermo Fisher Sci-
entific, #PA5-71878,); anti-MSP (1 lgmL1; R&D
Systems, #AF6244); anti-phospho-ERK1/2
(250 ngmL1; Cell Signaling Technology, #4370);
anti-ERK1/2 (84 ngmL1; Cell Signaling Technology,
#4695); anti-AKT (34 ngmL1; Cell Signaling Tech-
nology, #9272); anti-phospho-AKT (17 ngmL1; Cell
Signaling Technology, #4058); and anti-b-actin
(200 ngmL1; Sigma-Aldrich, #A5316, Dorset, UK).
HRP-linked secondary antibodies (Cell Signaling Tech-
nology, London, UK) were incubated for 1 h at room
temperature and proteins visualized by chemilumines-
cence (Thermo Fisher Scientific). Each experiment was
repeated at least four times.
2.5. ELISA
Macrophage-stimulating protein serum levels from
autochthonous KP and KB1P mice (n = 6) with mam-
mary tumors of greater than 12 mm or tumor-free,
Cre negative, littermate, wild-type (WT) mice (n = 5)
were measured using a kit from R&D Systems accord-
ing to the manufacturer’s recommendations.
2.6. Lentiviral transduction
Target sequences specific for Mst1r were designed
using the iRNAi program. shRNA oligos were gener-
ated and subcloned into the pLKO.1puro lentiviral
backbone using Addgene’s protocol (https://www.add
gene.org/8453/). Viral supernatants were prepared fol-
lowing transient transfection of 293FT cells with
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pLKO.1 encoding shRNAs, pSPAX2 packaging vector
and pVSVG envelope vector using Lipofectamine 2000
(Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. Two 24-
h supernatants were collected sequentially over a 48-h
period, pooled, and filtered through a 0.45-lm syringe
filter and then concentrated using the Lenti-X Concen-
trator solution (Clontech/Takara, Saint-Germain-en-
Laye, France). Freshly concentrated supernatants were
added directly to drained subconfluent recipient cells
and incubated overnight. An equal volume of fresh
medium was then added and antibiotic selection (puro-
mycin) initiated 48 h later. Antibiotic-resistant clones
were expanded for further analysis. We tested nine dif-
ferent shRNA oligos. Efficient Mst1r knockdown was
determined by quantitative real-time PCR, and two
distinct shRNAs were selected for further experiments.
Target sequences of the two oligos used for this study
were as follows: shRON-1 sense—CCTGCTGTATGT
GTCCAACTT, antisense—AAGTTGGACACATA-
CAGCAGG; shRON-2 sense—CGTCCTAGACAAG-
GAATACTA, antisense—TAGTATTCCTTGTCTAG
GACG.
2.7. Proliferation assay
Cellular proliferation was measured using the fluores-
cence-based proliferation CyQuant NF kit (Thermo
Fisher Scientific) according to the manufacturer’s
instructions. Cells were seeded in a 96-well plate, six
replicates per condition at 104 cells/well in low serum
(0.2%) for 72 h with daily administration of
100 ngmL1 MSP and/or 1 lM BMS-777607. Experi-
ments were repeated at least three times.
2.8. Immunohistochemistry
Immunohistochemical analyses were performed by the
Histology facility at the CRUK Beatson Institute using
standard protocols on Bond Rx or Dako autostainers.
Anti-Ki-67 (clone SP6; 1 : 100) was purchased from
Abcam, and anti-caspase 3 (clone Asp-175; 1 : 500)
was purchased from Cell Signaling. Quantitative analy-
sis of positive staining was performed by counting cells
in at least three high-power fields of view (940) per
tumor by two independent researchers who were
blinded to the sample group. Images were captured on
an Axio Imager A2 Bio upright microscope (Zeiss,
Cambridge, UK) using ZENPRO 2012 software (Zeiss).
2.9. cBioportal and oncomine analysis
cBioportal (cbioportal.org) was used for analysis of
the METABRIC (n = 1898 tumors) (Curtis et al.,
2012) and TCGA (n = 460 tumors) (Cancer Genome
Atlas, 2012) human breast cancer microarray datasets.
MST1 and MST1R mRNA expression was queried in
PAM50 molecular subsets. The data were exported as
a Z-score, which is a value of relative expression
among all samples that are diploid for the gene of
interest given as the number of standard deviations
away from the mean of expression of the diploid sam-
ples (described here: https://github.com/cBioPortal/cb
ioportal/blob/master/docs/Z-Score-normalization-sc
ript.md). The exported values were graphed with Prism
software. Similarly, Oncomine was used for the same
datasets to analyze MST1 and MST1R mRNA expres-
sion for TNBC versus non-TNBC. Here, information
was available for 1551 tumors in METABRIC and 349
tumors in TCGA. The data are displayed as log2 med-
ian-centered intensity.
2.10. Statistics
The nonparametric Mann–Whitney U-test was used to
compare two groups, while one-way ANOVA followed
by Dunn’s post hoc test was used to compare groups
of three or more. Two-way ANOVA with repeated
measures was used to analyze tumor growth curves.
The log-rank (Mantel–Cox) test was used to analyze
Kaplan–Meier survival curves. Sample sizes for each
experiment were based on a power calculation and/or
previous experience of the mouse models. Analyses
were performed using PRISM (version 8; GraphPad, San
Diego, CA, USA).
3. Results
3.1. MSP and its receptor, RON, are expressed in
autochthonous TNBC models
In previous studies, gene expression analysis of mam-
mary tumors from KP and KB1P mice by microarray
revealed that 646 genes are differentially expressed
between these two models of TNBC (Liu et al., 2007).
To identify targetable vulnerabilities in these mam-
mary tumors, we mined the 646 differentially expressed
genes for indicators of aberrant signaling pathways.
We found that the expression of the Mst1 gene—which
encodes the RON receptor ligand, MSP—is increased
in KB1P tumors when compared with KP tumors. We
analyzed RNA sequencing data from KP and KB1P
tumors for expression levels of Mst1 and Mst1r (Liu
et al., 2018). Mst1 levels were increased in KB1P
tumors when compared to normal mammary gland tis-
sue (MG) and KP tumors, while Mst1r levels were
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lower in both KP and KB1P tumors when compared
to MG (Fig. 1A). We validated these findings by real-
time PCR. Mst1 mRNA levels were significantly
higher in KB1P tumors, but Mst1r levels (measured by
primers that identify all isoforms) were the same
between tumor models (Fig. 1B). Expression levels of
MSP mirrored the mRNA levels and were greater in
KB1P compared to KP-derived tumor tissues
(Fig. 1C). Similarly, MSP serum levels were also ele-
vated in mammary tumor-bearing KB1P mice, when
compared to tumor-bearing KP mice or tumor-free,
WT mice (Fig. 1D). Western blot analysis of RON
expression revealed multiple isoforms of the RON
receptor (Fig. 1E). The short form of RON (sfRON)
was most prevalent and, in keeping with the qRT–
PCR analysis, was expressed to approximately equiva-
lent levels in both tumor models. The prevalence of
sfRON in these mouse models is consistent with
human breast cancer, where the short form is the
major RON isoform expressed (Liu et al., 2011). The
b chain-containing long forms of RON (lfRON) con-
sist of various spliced isoforms or post-translationally
modified isoforms that can bind MSP (Yao et al.,
2013). In contrast to sfRON which was equally
expressed between KP and KB1P tumors, we found
that lfRON was differentially expressed between KP
and KB1P tumors, where four out of five KB1P
tumors robustly expressed an isoform at about
130 kDa (Fig. 1E). Only one of the five KP tumors
showed expression of this isoform. Of the remaining
four KP tumors, three tumors expressed a higher
molecular weight form, and one tumor expressed no
detectable lfRON (Fig. 1E). Quantification of the com-
bined lfRON band intensities revealed overall higher
expression levels in KB1P compared to KP tumors
(Fig. 1E). Together these data reveal that the MSP
specific form of the RON receptor was differentially
expressed between KP and KB1P tumor models, and
the sfRON, which lacks the MSP binding domain and
remains unresponsive to MSP, was present at high
levels in both tumor models.
3.2. MSP–RON signaling activates AKT and
MAPK pathways
We derived cell lines from tumors in three independent
KP mice and four independent KB1P mice, and per-
formed qRT–PCR analysis to examine the expression
of Mst1 and Mst1r mRNA in vitro. As shown in
Fig. 2A, Mst1 and Mst1r transcripts persisted in all
cell lines. Expression levels of Mst1 and Mst1r were
similar between the three KP cell lines, the four KB1P
cell lines as well as between KP and KB1P cell lines.
These data were consistent with primary tumor data
for Mst1r mRNA, but different for Mst1 mRNA
where both mRNA and protein levels were increased
in KB1P tumors compared with KP tumors (Fig. 1B).
Protein expression of MSP and RON was then mea-
sured by western blot analysis in the same cell lines. In
contrast to the primary tumor tissue (Fig. 1C), MSP
expression was equivalent between KP and KB1P cell
lines (Fig. 2B). RON protein expression in the cell
lines was also different than the pattern observed in
primary tumors. A single band corresponding to the
lfRON was the predominant species detected, and it
was expressed to approximately equivalent levels in
each cell line (Fig. 2B). The expression of sfRON also
persisted, but the ratio between the long and short
forms had increased compared to the primary tumors.
These data indicate that there are several discrepancies
in expression levels of MSP and RON between in vivo
and in vitro tissue samples. The discrepancies may be
explained by the fact that either cancer cells grown on
plastic must adapt to 2D culture or other cell types in
KB1P tumors express MSP in addition to cancer
epithelial cells.
To determine which signaling pathways are acti-
vated by MSP in these mammary cancer cell lines, we
used the KP-1, KP-2, KB1P-1, and KB1P-2 cell lines
from Fig. 2B. We hypothesized that MSP would
induce similar activation of AKT and ERK1/2 in both
KP and KB1P cells, given that RON is expressed at
the same levels in the two cell types (Fig. 2B). As
shown in Fig. 2C, MSP treatment induced robust sig-
naling responses, inducing phosphorylation of AKT
and ERK1/2 in all four cell lines. To confirm that
MSP is acting through the RON receptor, KP and
KB1P cells were preincubated with a RON inhibitor,
BMS-777607. For both cell lines, preincubation with
BMS-777607 effectively reduced phosphorylation of
AKT and ERK1/2 in response to MSP stimulation.
KP-1 and KB1P-1 cells were more sensitive to the inhi-
bitor than the other cells based on the greater decrease
in phosphorylation of ERK1/2 (Fig. 2C). To confirm
selectivity against RON (since BMS-777607 is not
absolutely specific for the RON receptor), we repeated
these experiments using an shRNA-mediated knock-
down approach to silence Mst1r expression in KB1P
cells (Fig. 2D). Mirroring pharmacological inhibition
of RON, MSP treatment of KB1P cells lacking RON
failed to increase phosphorylation of both AKT and
ERK1/2 (Fig. 2E). These data indicate that MSP stim-
ulates robust intracellular signaling pathways via the
RON receptor.
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Fig. 1. MSP and RON are upregulated in tumors from KB1P mice. (A) Mst1 and Mst1r mRNA expression in normal MG (from three individual
mice), KP tumors (n = 44) and KB1P tumors (n = 41) analyzed by RNA sequencing. Boxplots represent the median, and 25th and 75th
percentiles. (B)Mst1 andMst1rmRNA expression in KP and KB1P tumors assessed by qRT–PCR (n = 7/group). (C) Western blot analysis of MSP
expression in KP and KB1P tumors with densitometric quantification. Numbers above the blot represent individual tumors. Each dot represents
one donor tumor from one mouse. (D) MSP serum levels in tumor-free, WT (n = 5) mice, tumor-bearing KP (n = 6) mice, and tumor-bearing KB1P
(n = 6) mice assessed by ELISA. (E) Western blot analysis of RON protein expression in KP and KB1P tumors (same samples as in C) with
densitometric quantification. Numbers above the blot represent individual tumors. Each dot represents one donor tumor from one mouse. For C
and E, b-actin was used as sample integrity control (same sample, different blot). Data are represented as mean  SD. *P < 0.05, **P < 0.01,
***P < 0.001 as determined byMann–WhitneyU-test (A, B, C, E) or one-way ANOVA followed by Dunn’s post hoc test (D). n.s., not significant.
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3.3. The MSP–RON axis promotes cell
proliferation
We examined the functional effects of MSP–RON sig-
naling on proliferation of the four KP and KB1P cell
lines, since both AKT and ERK pathways are known
to regulate cell division. We found that MSP increased
proliferation of all cell lines, and that proliferation
could be attenuated by addition of BMS-777607
(Fig. 3A). Treatment of the KB1P cell lines with BMS-
777607 alone had no effect on cell proliferation com-
pared with untreated control cells, but the inhibitor on
its own was able to reduce proliferation in the two KP
cell lines (Fig. 3A). Moreover, shRNA-mediated RON
Fig. 2. MSP stimulates AKT and MAPK signaling pathways through the RON receptor. (A) Mst1r mRNA expression assessed by qRT–PCR
in cell lines derived from three KP tumors and four KB1P tumors, respectively. (B) Western blot analysis of RON protein expression in the
same cell lines used in A. b-Actin was used as sample integrity control (same sample, different blot). (C) Western blot analysis of indicated
proteins in the same KP and KB1P cell lines used in A, B. Cells were pretreated with 1 lM BMS-777607 for 1 h prior to 100 ngmL1
recombinant MSP for 1 h where denoted. Images are representative of three replicate experiments. Total AKT and ERK were probed on the
same blot as sample integrity controls. (D) Two KB1P cell lines were transduced with lentiviral shRNA vectors against Mst1r mRNA
(shRON-1 or shRON-2) or control pLKO.1 vector. Confirmation of Mst1r mRNA knockdown quantified by qRT–PCR is expressed as relative
to two housekeeping genes, Hprt and b-actin (each dot represents one technical replicate in a given experiment, the experiment was
repeated three times for each cell line). (E) Two independent KB1P cell lines transduced with control or shRNA vectors against Mst1r
mRNA were treated with 100 ngmL1 recombinant MSP for 1 h. Activation of AKT and ERK1/2 was assessed by western blot. Images are
representative of three replicate transduction experiments. Data are represented as mean  SD. **P < 0.01 as determined by one-way
ANOVA followed by Dunn’s post hoc test. n.s., not significant.
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depletion, using two shRNAs separately in each KB1P
cell line, significantly reduced proliferation after MSP
treatment (Fig. 3B). These data indicate that MSP
requires long-form RON for its mitogenic effects.
3.4. Inhibition of RON delays tumor growth
in vivo
Next, we transplanted tumor fragments from KB1P
mice into the mammary gland of syngeneic FVB/n
mice. When tumors were palpable, we treated the mice
with BMS-777607 or vehicle control and monitored
tumor growth until humane end-point. Inhibition of
RON in KB1P mammary tumor-bearing mice delayed
tumor growth. This difference was statistically signifi-
cant (P < 0.01) beginning from day 13 (Fig. 4A). In
addition, KB1P tumor-bearing mice treated with
BMS-777607 survived significantly longer (7 days)
when compared to the control cohort (Fig. 4B). To
gain insight into how RON signaling potentiates
tumorigenesis, mice transplanted with KB1P tumor
fragments were treated with BMS-777607 or vehicle
Fig. 3. MSP activation of the RON receptor induces proliferation of KP and KB1P cells in vitro. (A) Proliferation of two KP and two KB1P cell
lines in response to 100 ngmL1 MSP, 1 µM BMS-777607, or both reagents. For combined treatments, cells were pretreated with BMS-
777607 for 1 h before the addition of MSP. For all treatments, cells were re-fed every 24 h with fresh MSP and BMS-777607 as denoted.
DNA content was measured at 72 h post-treatment. (B) Proliferation of two KP and two KB1P cell lines transduced with control pLKO.1 or
shRNA vectors against Mst1r mRNA following 48-h treatment with recombinant MSP as above. For both A and B, data points shown are
technical replicates from 1 representative experiment from three repeated experiments. Data are represented as mean  SD. *P < 0.05,
**P < 0.01, ***P < 0.001 as determined by one-way ANOVA followed by Dunn’s post hoc test.
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control for 7 days and then euthanized to examine the
growing tumors histologically. The number of Ki-67+
cells and caspase 3+ cells was measured as surrogate
markers for proliferation and apoptosis, respectively.
Tumor sections from BMS-777607-treated mice exhib-
ited less Ki-67+ cells when compared to controls
(Fig. 4C), whereas caspase 3+ cells were similar
between both groups (Fig. 4D). Together these data
indicate that RON inhibition slows cancer cell prolifer-
ation without affecting apoptosis and suggest that, in
the KB1P model, the MSP–RON axis plays an impor-
tant role in cancer progression.
3.5. MSP and RON are expressed across human
breast cancer subtypes
Previous studies have shown that MST1 mRNA and
RON protein are increased in human ductal breast
carcinoma tissue when compared to normal breast tis-
sue (Benight et al., 2015; Maggiora et al., 1998).
Whether MSP or RON expression is specifically
altered across subsets of human breast cancer is
unknown. To address this question, we probed the
METABRIC (Curtis et al., 2012) and TCGA (Cancer
Genome Atlas, 2012) datasets on cBioportal for MST1
and MST1R mRNA expression using the PAM50
breast cancer subsets to divide the samples. The
PAM50 is a 50-gene PCR assay used to identify Lum-
nial A, Luminal B, HER2-enriched, basal-like, nor-
mal-like, and claudin-low breast tumors (Perou et al.,
2000). The claudin-low subset was absent from TCGA
data. The identification of the specific RON isoform
probed in these microarrays was unknown. Both data-
sets showed significant differences between the PAM50
subsets for MST1 expression (Fig. 5A). In the
METABRIC dataset, MST1 expression was highest in
normal-like breast tumors and lowest in claudin-low
breast tumors. This observation was not recapitulated
for the TCGA dataset, where MST1 expression was
highest in Luminal A breast tumors and lowest in
HER2 breast tumors (Fig. 5A). For MST1R expres-
sion, statistical differences between PAM50 subsets
were only observed in the METABRIC dataset;
expression was highest in HER2 breast tumors and
lowest in claudin-low breast tumors (Fig. 5B). In the
TCGA dataset, MST1R expression levels were statisti-
cally equivalent (Fig. 5B). Next, we analyzed MST1
and MST1R mRNA expression in histologically
defined samples, comparing TNBC with all other sub-
groups, such as ER+ and HER2+, using Oncomine.
This analysis revealed that MST1 and MST1R expres-
sion is similar between TNBC and other subgroups in
both the METABRIC and TCGA datasets (Fig. 5C).
Given the lack of consistency in expression differences
between PAM50 subsets in the METABRIC and
TCGA datasets and the lack of difference between his-
tological subgroups, these data indicate that MST1
and MST1R expression is mostly uniform across
human breast cancer subtypes.
4. Discussion
In this study, we found that MSP signaling via its
receptor, RON, is critical for growth and proliferation
of KP and KB1P mammary cancer cells both in vitro
and in vivo. These data accord well with previous pub-
lications in other mammary tumor models that rely on
artificial, ectopic expression of MSP or the RON
receptor (Andrade et al., 2017; Benight et al., 2015;
Cunha et al., 2014; Ekiz et al., 2018; Eyob et al., 2013;
Welm et al., 2007; Zinser et al., 2006). Most mechanis-
tic work on the MSP–RON axis has used cell lines
derived from the MMTV-PyMT model (Andrade
et al., 2017; Ekiz et al., 2018; Eyob et al., 2013; Welm
et al., 2007) that overexpress MSP, or genetically engi-
neered mouse models in which Mst1r expression is dri-
ven by the MMTV promoter (Benight et al., 2015;
Zinser et al., 2006). The KB1P model provides a new
resource to interrogate the importance of MSP and
RON in a nonviral oncogenic model that better mim-
ics breast cancer etiology.
Our findings provide additional insight into the role
of RON isoforms in cancer progression. We show that
primary mammary tumors from the KP and KB1P
models express multiple isoforms of RON with the
short form being the most dominant. Full-length RON
and short-form RON mRNA are initiated from differ-
ent transcriptional start sites (Yao et al., 2013),
although the regulation of these isoforms in KP and
KB1P mammary cancer cells is unknown. When cell
lines were generated from these two models, the
expression of the longer forms of RON (lfRON)
equaled the expression of the sfRON. These data indi-
cate a discrepancy between tumors in situ and mam-
mary cancer cell lines grown on plastic that should be
considered when designing experiments. This observa-
tion also suggests that persistence of the long form of
RON provides an advantage to cancer cells grown in
culture. Both long and short isoforms of RON are
inhibited by BMS-777607. Interestingly, treatment of
two independent KB1P cell lines with BMS-777607
alone (in the absence of MSP) failed to block prolifer-
ation, suggesting that short-form RON is less impor-
tant for cell growth of KB1P cells than the long form,
which requires MSP for activation. By contrast, the
KP cell lines were sensitive to BMS-777607 treatment
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alone, suggesting that sfRON is important in the KP
model. However, we cannot rule out blocking of other
molecules by the inhibitor. The cMET oncogene is
overexpressed in the KP model (Liu et al., 2018), so
the decrease in KP cell proliferation after BMS-777607
treatment may be partially explained by the inhibition
of MET.
Another interesting observation from this work was
the upregulation of MSP and RON expression in
breast cancer 1 (BRCA1)-deficient mammary tumors
compared to BRCA1 WT tumors, which suggests
that MSP–RON signaling may be evolutionarily
selected in highly genomically unstable tumors. A
previous publication exhaustively characterized copy
Fig. 4. Inhibition of RON signaling reduces KB1P tumor growth in mice. Mice were transplanted with KB1P tumor fragments from one
donor tumor. Once tumors reached 3 9 3 mm, mice were treated daily with 50 mgkg1 BMS-777607 or vehicle control for 10 days in A, B
(n = 6/group) and 7 days in C, D (n = 5/group for BMS-777607 and n = 6/group for control). (A) Tumor growth was measured by calipers
twice per week and represented graphically. Dark solid lines indicate the mean of each group, while thin lines indicate individual mice.
Black = vehicle control, blue = BMS-777607. Tumor growth was significantly different (P < 0.01 as determined by two-way ANOVA)
between groups beginning on day 13. (B) Kaplan–Meier survival analysis of the mice depicted in C euthanized when tumors reached
15 9 15 mm in size. Statistical difference was calculated by Mantel–Cox test. (C, D) Tumor sections were processed by
immunohistochemistry for (C) Ki-67 and (D) cleaved caspase 3. Staining was quantified by counting positive cells in at least three 409 fields
of view per tumor. Each dot represents one tumor. Representative images are shown at 409 for each stain from control or BMS-777607-
treated tumors. Data are represented as mean  SD. *P < 0.05 as determined by Mann–Whitney U-test. n.s., not significant.
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number alterations in tumors from the KP and KB1P
models and showed that allele frequency of Mst1 and
Mst1r genes is normal in both tumor types, without
amplification or deletion (Liu et al., 2018). Since
upregulation of MSP and RON in KB1P tumors can-
not be explained by increased copy number, it would
seem that overactive transcription and/or translation
are the most likely cause. We found that the genes
encoding MSP and RON in human breast tissue
largely failed to correlate with PAM50 subsets or his-
tological hormone receptor status. However, we were
unable to determine which isoform of RON was
detected in the microarray data, indicating that some
RON isoforms may be differentially expressed
between human breast cancer subsets. In future stud-
ies, it will be interesting to determine whether the
MSP–RON axis is enriched in genomically unstable
human tumors.
Fig. 5. MST1 and MST1R mRNA
expression in human breast cancer.
(A, B) METABRIC and TCGA
datasets were analyzed for (A)
MST1 and (B) MST1R mRNA
expression in PAM50 gene
signature subsets using cBioportal.
The METABRIC dataset included
679 Luminal A tumors, 461 Luminal
B tumors, 220 HER2 tumors, 140
normal-like tumors, 199 basal-like
tumors, and 199 claudin-low
tumors. The TCGA dataset included
208 Luminal A tumors, 110 Luminal
B tumors, 53 HER2 tumors, eight
normal-like tumors, and 81 basal-
like tumors. Boxplots represent the
median  minimum/maximum
values. P values were determined
by one-way ANOVA. (C) Oncomine
was used to analyze MST1 and
MST1R mRNA expression by
histological hormone status in
METABRIC (TNBC n = 211, other
n = 1340) and TCGA (TNBC n = 49,
other n = 300) datasets. Boxplots
represent the median  minimum/
maximum values. P values were
determined by Mann–Whitney U-
test. n.s., not significant.
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5. Conclusion
Our results show that the MSP–RON axis is specifically
upregulated in a BRCA1-deficient autochthonous mouse
model of TNBC. Pharmacological or genetic inhibition
of the RON receptor resulted in attenuated AKT and
MAPK signaling and reduced cell growth in vitro,
whereas manipulation of the pathway significantly
improved survival and delayed tumor growth in vivo.
These data identify a clinically relevant model system
that will be useful to study the biology and therapeutic
targeting of theMSP–RON signaling pathway in vivo.
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